Document Detail


Reactivation of human polyomavirus JC in patients affected by psoriasis vulgaris and psoriatic arthritis and treated with biological drugs: preliminary results.
MedLine Citation:
PMID:  22422468     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Psoriasis vulgaris (PsV) and psoriatic arthritis (PSA) are inter-related heritable inflammatory skin diseases. Psoriatic lesions develop as a result of abnormal immune responses, hyperproliferation and altered differentiation of keratinocytes, and a notable subset of psoriatic patients develops PsA, characterized by joints inflammation. Recently, biological drugs were introduced to treat these diseases. However, this therapy has already been associated with the development of serious life-threatening infections, such as the reactivation of human polyomavirus JC (JCV), responsible for the progressive multifocal leukoencephalopathy (PML), a lethal demyelinating disease caused by oligodendrocytes lytic infection. Therefore, the aims of our study were the investigation of the possible JCV reactivation in PsV and PsA patients treated with adalimumab, etanercept, and methotrexate, performing quantitative real-time PCR in sera and skin biopsies at the time of recruitment (T0) and after 3 (T3) and 6 (T6) months of treatment, and the sequencing analysis of the JCV non-coding control region (NCCR). We found JCV DNA in 5/15 PsV patients and in 2/15 PsA patients and JCV NCCR sequence analysis always showed a structure similar to non-pathogenic CY archetype, with random occurrence of a few irrelevant point mutations. Nevertheless the poor number of patients analyzed, our preliminary data can pave the way for taking into account that the follow-up of JCV DNA detection and the JCV NCCR sequence analysis in psoriatic patients may be important to evaluate the risk of PML onset, considering that patients affected by autoimmune diseases and treated with biologics continue to rise.
Authors:
Chiara Nardis; Elena Anzivino; Anna Bellizzi; Donatella M Rodio; Ornella De Pità; Fernanda Chiarini; Valeria Pietropaolo
Related Documents :
8676168 - Simple partial status epilepticus: causes, treatment, and outcome in 47 patients.
17621818 - Endoscopic management of sinus disease with frontal lobe displacement.
16504478 - Evaluation of cacna1h in european patients with childhood absence epilepsy.
20174788 - Diffusion tensor tract-specific analysis of the uncinate fasciculus in patients with am...
24518408 - Prevalence and clinical significance of spontaneous low-frequency air-bone gaps in mén...
20118768 - Identification of histologically distinct conventional adenomas that arise predominatel...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of cellular physiology     Volume:  227     ISSN:  1097-4652     ISO Abbreviation:  J. Cell. Physiol.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-08-28     Completed Date:  2012-11-06     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0050222     Medline TA:  J Cell Physiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3796-802     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Wiley Periodicals, Inc.
Affiliation:
Department of Health Sciences and Infectious Diseases, Sapienza University, Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antibodies, Monoclonal, Humanized / pharmacology,  therapeutic use
Antigens, Viral / analysis
Arthritis, Psoriatic / complications,  drug therapy,  immunology
Base Sequence
DNA, Viral / analysis,  chemistry
Female
Humans
Immunoglobulin G / pharmacology,  therapeutic use
Immunosuppressive Agents / pharmacology,  therapeutic use*
JC Virus / physiology*
Male
Molecular Sequence Data
Polymerase Chain Reaction
Polyomavirus Infections / pathology,  virology*
Psoriasis / complications,  drug therapy*,  immunology
Receptors, Tumor Necrosis Factor / therapeutic use
Tumor Virus Infections / pathology,  virology*
Virus Activation / drug effects,  immunology*
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Antigens, Viral; 0/DNA, Viral; 0/Immunoglobulin G; 0/Immunosuppressive Agents; 0/Receptors, Tumor Necrosis Factor; 185243-69-0/TNFR-Fc fusion protein; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Human mesenchymal stem cells are recruited to injured liver in a ?1-integrin and CD44 dependent mann...
Next Document:  Modulation of Hepatic Drug Metabolizing Enzymes by Dietary Doses of Thymoquinone in Female New Zeala...